Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples